{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T10:55:19Z","timestamp":1793271319740,"version":"4.5.0"},"reference-count":129,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.biopsych.2016.03.2104","type":"journal-article","created":{"date-parts":[[2016,4,2]],"date-time":"2016-04-02T01:07:55Z","timestamp":1459559275000},"page":"31-42","source":"Crossref","is-referenced-by-count":285,"title":["Pathway-Specific Dopamine Abnormalities in Schizophrenia"],"prefix":"10.1016","volume":"81","author":[{"given":"Jodi J.","family":"Weinstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad O.","family":"Chohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Slifstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence S.","family":"Kegeles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anissa","family":"Abi-Dargham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2016.03.2104_bib1","first-page":"492","article-title":"The significance of dopamine receptor blockade for the mechanism of action of neuroleptic drugs","volume":"160","author":"Rossum","year":"1966","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1176\/ajp.135.2.164","article-title":"Antipsychotic drugs, neurotransmitters, and schizophrenia","volume":"135","author":"Carlsson","year":"1978","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib3","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/261717a0","article-title":"Antipsychotic drug doses and neuroleptic\/dopamine receptors","volume":"261","author":"Seeman","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/BF00216006","article-title":"Provocative tests with psychostimulant drugs in schizophrenia","volume":"91","author":"Lieberman","year":"1987","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/schbul\/14.2.157","article-title":"Speculation on the meaning of cerebral metabolic hypofrontality in schizophrenia","volume":"14","author":"Weinberger","year":"1988","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib6","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1176\/ajp.148.11.1474","article-title":"Dopamine in schizophrenia: a review and reconceptualization","volume":"148","author":"Davis","year":"1991","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/schbul\/22.2.283","article-title":"Monitoring and care of young people at incipient risk of psychosis","volume":"22","author":"Yung","year":"1996","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1192\/S0007125000297602","article-title":"Prediction of psychosis. A step towards indicated prevention of schizophrenia","volume":"172","author":"Yung","year":"1998","journal-title":"Br J Psychiatry Suppl"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/archgenpsychiatry.2008.514","article-title":"Elevated striatal dopamine function linked to prodromal signs of schizophrenia","volume":"66","author":"Howes","year":"2009","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1503\/jpn.110181","article-title":"Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task","volume":"38","author":"Suridjan","year":"2013","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib11","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/npp.2013.347","article-title":"Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use","volume":"39","author":"Mizrahi","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0893-133X(99)00153-0","article-title":"Effects of acute metabolic stress on striatal dopamine release in healthy volunteers","volume":"22","author":"Adler","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib13","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1523\/JNEUROSCI.3422-03.2004","article-title":"Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: A positron emission tomography study using [11C]raclopride","volume":"24","author":"Pruessner","year":"2004","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.biopsych.2011.10.009","article-title":"Increased stress-induced dopamine release in psychosis","volume":"71","author":"Mizrahi","year":"2012","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib15","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1038\/sj.npp.1301597","article-title":"Stress-induced dopamine release in humans at risk of psychosis: A [11C]raclopride PET study","volume":"33","author":"Soliman","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib16","first-page":"316","article-title":"Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: A positron emission tomographic functional magnetic resonance imaging study. JAMA","volume":"72","author":"Slifstein","year":"2015","journal-title":"Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib17","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.jcbfm.9600493","article-title":"Consensus nomenclature for in vivo imaging of reversibly binding radioligands","volume":"27","author":"Innis","year":"2007","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib18","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0969-8051(01)00214-1","article-title":"Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers","volume":"28","author":"Slifstein","year":"2001","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib19","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00213-004-1830-x","article-title":"In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates","volume":"175","author":"Slifstein","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib20","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0969-8051(94)00117-3","article-title":"Fluorinated benzamide neuroleptics\u2014III. development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer","volume":"22","author":"Mukherjee","year":"1995","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib21","first-page":"1275","article-title":"Carbon-11-FLB 457: A radioligand for extrastriatal D2 dopamine receptors","volume":"36","author":"Halldin","year":"1995","journal-title":"J Nucl Med"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0014-2999(92)90825-O","article-title":"Visualization of extrastriatal dopamine D2 receptors in the human brain","volume":"223","author":"Kessler","year":"1992","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib23","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/syn.20325","article-title":"The dopamine (D-2\/3) receptor agonist positron emission tomography radiotracer [C-11)-(+)-PHNO is a D-3 receptor preferring agonist in vivo","volume":"60","author":"Narendran","year":"2006","journal-title":"Synapse"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib24","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/syn.20658","article-title":"In vivo quantification of regional dopamine-D3 receptor binding potential of (+)PHNO: Studies in non-hman primates and transgenic mice","volume":"63","author":"Rabiner","year":"2009","journal-title":"Synapse"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib25","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1021\/jm050155n","article-title":"Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography","volume":"48","author":"Wilson","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00004647-200002000-00003","article-title":"Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with [11C]NNC 112 in humans: Validation and reproducibility","volume":"20","author":"Abi-Dargham","year":"2000","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib27","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/385634a0","article-title":"Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET","volume":"385","author":"Okubo","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib28","series-title":"Dopamine in the CNS","first-page":"63","article-title":"Synaptology of dopamine neurons","author":"Sesack","year":"2002"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib29","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.neubiorev.2009.05.005","article-title":"The dopaminergic basis of human behaviors: A review of molecular imaging studies","volume":"33","author":"Egerton","year":"2009","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1523\/JNEUROSCI.14-01-00088.1994","article-title":"Ultrastructural localization of D2 receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets","volume":"14","author":"Sesack","year":"1994","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib31","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1523\/JNEUROSCI.15-07-05222.1995","article-title":"Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents","volume":"15","author":"Hersch","year":"1995","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib32","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/0306-4522(94)00536-E","article-title":"Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: Light and electron microscopy","volume":"65","author":"Yung","year":"1995","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib33","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00004647-200003000-00001","article-title":"Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review","volume":"20","author":"Laruelle","year":"2000","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/(SICI)1098-2396(199805)29:1<37::AID-SYN4>3.0.CO;2-C","article-title":"Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms","volume":"29","author":"Cumming","year":"1998","journal-title":"Synapse"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib35","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/sj.jcbfm.9600079","article-title":"PET studies of net blood-brain clearance of FDOPA to human brain: Age-dependent decline of [18F]fluorodopamine storage capacity","volume":"25","author":"Kumakura","year":"2005","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib36","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00004647-200104000-00015","article-title":"A reversible tracer analysis approach to the study of effective dopamine turnover","volume":"21","author":"Sossi","year":"2001","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.pscychresns.2007.11.003","article-title":"Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA","volume":"163","author":"Cropley","year":"2008","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib38","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1212\/WNL.42.8.1573","article-title":"Striatal monoamine neurotransmitters and metabolites in dominantly inherited olivopontocerebellar atrophy","volume":"42","author":"Kish","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib39","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/jcbfm.1994.131","article-title":"Graphical, kinetic and equilibrium analysis of [123-I]b-CIT in vivo binding to dopamine transporters in healthy subjects","volume":"14","author":"Laruelle","year":"1994","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib40","doi-asserted-by":"crossref","first-page":"11651","DOI":"10.1073\/pnas.91.24.11651","article-title":"Elevated dopa decarboxylase activity in living brain of patients with psychosis","volume":"91","author":"Reith","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib41","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S0140-6736(95)91801-9","article-title":"Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients","volume":"346","author":"Hietala","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib42","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0920-9964(98)00113-3","article-title":"Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia","volume":"35","author":"Hietala","year":"1999","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib43","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nn804","article-title":"Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia","volume":"5","author":"Meyer-Lindenberg","year":"2002","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib44","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/archpsyc.61.2.134","article-title":"Presynaptic dopaminergic dysfunction in schizophrenia: A positron emission tomographic [18F]fluorodopa study","volume":"61","author":"McGowan","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib45","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0006-3223(99)00109-2","article-title":"Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET","volume":"46","author":"Lindstrom","year":"1999","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib46","doi-asserted-by":"crossref","first-page":"8080","DOI":"10.1523\/JNEUROSCI.0805-07.2007","article-title":"Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: An [18F]fluorodopa\/positron emission tomography study","volume":"27","author":"Kumakura","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib47","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.schres.2008.11.006","article-title":"Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PET","volume":"108","author":"Nozaki","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0925-4927(00)00064-0","article-title":"6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography","volume":"100","author":"Elkashef","year":"2000","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib49","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0920-9964(96)00102-8","article-title":"Presynaptic dopaminergic function in the striatum of schizophrenic patients","volume":"23","author":"Dao-Castellana","year":"1997","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib50","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/schbul\/sbr180","article-title":"Striatal presynaptic dopamine in schizophrenia, part II: Meta-analysis of [(18)F\/(11)C]-DOPA PET studies","volume":"39","author":"Fusar-Poli","year":"2013","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib51","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/archgenpsychiatry.2012.169","article-title":"The nature of dopamine dysfunction in schizophrenia and what this means for treatment","volume":"69","author":"Howes","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib52","doi-asserted-by":"crossref","first-page":"9235","DOI":"10.1073\/pnas.93.17.9235","article-title":"Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects","volume":"93","author":"Laruelle","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib53","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1176\/ajp.155.6.761","article-title":"Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort","volume":"155","author":"Abi-Dargham","year":"1998","journal-title":"Am J Psychiatry"},{"issue":"suppl 1","key":"10.1016\/j.biopsych.2016.03.2104_bib54","first-page":"S36","article-title":"Dopaminergic neurotransmission in patients with schizophrenia in relation to positive and negative symptoms","volume":"45","author":"Pogarell","year":"2012","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib55","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1073\/pnas.94.6.2569","article-title":"Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method","volume":"94","author":"Breier","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib56","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0006-3223(99)00067-0","article-title":"Increased dopamine transmission in schizophrenia: Relationship to illness phases","volume":"46","author":"Laruelle","year":"1999","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib57","doi-asserted-by":"crossref","first-page":"8104","DOI":"10.1073\/pnas.97.14.8104","article-title":"Increased baseline occupancy of D2 receptors by dopamine in schizophrenia","volume":"97","author":"Abi-Dargham","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib58","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.biopsych.2008.12.007","article-title":"Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects","volume":"65","author":"Abi-Dargham","year":"2009","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib59","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1001\/archgenpsychiatry.2010.10","article-title":"Increased synaptic dopamine function in associative regions of the striatum in schizophrenia","volume":"67","author":"Kegeles","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib60","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0006-3223(94)00202-E","article-title":"Age-related changes in [3H]GBR 12935 binding site density in the prefrontal cortex of controls and schizophrenics","volume":"37","author":"Hitri","year":"1995","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib61","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0893-133X(00)00165-2","article-title":"In vivo measurement of the vesicular monoamine transporter in schizophrenia","volume":"23","author":"Taylor","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib62","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1176\/appi.ajp.157.2.269","article-title":"Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography","volume":"157","author":"Laakso","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib63","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0006-3223(99)00257-7","article-title":"Dopamine and serotonin transporters in patients with schizophrenia: An imaging study with [(123)I]beta-CIT","volume":"47","author":"Laruelle","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib64","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0920-9964(00)00095-5","article-title":"Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia","volume":"52","author":"Laakso","year":"2001","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib65","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0920-9964(00)00023-2","article-title":"Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT","volume":"47","author":"Lavalaye","year":"2001","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib66","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0920-9964(03)00006-9","article-title":"Dopamine transporter change in drug-naive schizophrenia: An imaging study with 99mTc-TRODAT-1","volume":"65","author":"Hsiao","year":"2003","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib67","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.schres.2007.11.010","article-title":"Dual-isotope SPECT imaging of striatal dopamine: First episode, drug naive schizophrenic patients","volume":"101","author":"Schmitt","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib68","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00213-006-0570-5","article-title":"Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait","volume":"191","author":"Mateos","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib69","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00213-005-2250-2","article-title":"Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism","volume":"181","author":"Mateos","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib70","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.schres.2004.03.015","article-title":"Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia","volume":"71","author":"Yoder","year":"2004","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib71","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1176\/appi.ajp.161.8.1496","article-title":"Associated alterations of striatal dopamine D2\/D3 receptor and transporter binding in drug-naive patients with schizophrenia: A dual-isotope SPECT study","volume":"161","author":"Yang","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib72","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.jpsychires.2009.04.009","article-title":"Increase in thalamic binding of [(11)C]PE2I in patients with schizophrenia: A positron emission tomography study of dopamine transporter","volume":"43","author":"Arakawa","year":"2009","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib73","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1176\/appi.ajp.159.5.761","article-title":"P.E.T. study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia","volume":"159","author":"Karlsson","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib74","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1523\/JNEUROSCI.22-09-03708.2002","article-title":"Prefrontal dopamine D1 receptors and working memory in schizophrenia","volume":"22","author":"Abi-Dargham","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib75","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1177\/0269881111409265","article-title":"Increased prefrontal cortical D1 receptors in drug naive patients with schizophrenia: A PET study with [11C]NNC112","volume":"26","author":"Abi-Dargham","year":"2012","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib76","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1176\/appi.ajp.2011.11010160","article-title":"Dopamine synthesis capacity before onset of psychosis: A prospective [18F]-DOPA PET imaging study","volume":"168","author":"Howes","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib77","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/archgenpsychiatry.2010.77","article-title":"Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study","volume":"67","author":"Fusar-Poli","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib78","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/mp.2009.108","article-title":"Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis","volume":"16","author":"Fusar-Poli","year":"2011","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib79","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/mp.2011.20","article-title":"Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: A PET study","volume":"16","author":"Howes","year":"2011","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib80","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.biopsych.2012.11.017","article-title":"Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: Findings in a second cohort","volume":"74","author":"Egerton","year":"2013","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib81","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1176\/appi.ajp.2012.12010144","article-title":"Dopamine synthesis capacity in patients with treatment-resistant schizophrenia","volume":"169","author":"Demjaha","year":"2012","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib82","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/mp.2012.109","article-title":"Striatal dopamine release in schizophrenia comorbid with substance dependence","volume":"18","author":"Thompson","year":"2013","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib83","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1017\/S1461145703003699","article-title":"Decreased thalamic D2\/D3 receptor binding in drug-naive patients with schizophrenia: A PET study with [11C]FLB 457","volume":"6","author":"Talvik","year":"2003","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib84","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/archpsyc.59.1.25","article-title":"Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia","volume":"59","author":"Suhara","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib85","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.biopsych.2006.01.010","article-title":"Frontal dopamine D(2\/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender","volume":"60","author":"Glenthoj","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib86","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.biopsych.2010.05.027","article-title":"Striatal and extrastriatal dopamine D2\/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography","volume":"68","author":"Kegeles","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib87","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.biopsych.2008.12.029","article-title":"Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects","volume":"65","author":"Kessler","year":"2009","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib88","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1192\/bjp.bp.113.132308","article-title":"Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: Systematic review and meta-analysis of imaging studies","volume":"204","author":"Kambeitz","year":"2014","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib89","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.lfs.2010.03.018","article-title":"Decreased binding of [11C]NNC112 and [11C]SCH23390 in patients with chronic schizophrenia","volume":"86","author":"Kosaka","year":"2010","journal-title":"Life Sci"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib90","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00213-013-3026-8","article-title":"In vivo binding of the dopamine-1 receptor PET tracers [11C]NNC112 and [11C]SCH23390: A comparison study in individuals with schizophrenia","volume":"228","author":"Poels","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib91","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1093\/brain\/awt264","article-title":"Midbrain dopamine function in schizophrenia and depression: A post-mortem and positron emission tomographic imaging study","volume":"136","author":"Howes","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib92","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1093\/schbul\/sbr194","article-title":"Transition to psychosis associated with prefrontal and subcortical dysfunction in ultra high-risk individuals","volume":"38","author":"Allen","year":"2012","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib93","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0006-3223(00)00981-1","article-title":"Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects","volume":"49","author":"Zubieta","year":"2001","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib94","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.schres.2010.03.043","article-title":"18F-fallypride binding potential in patients with schizophrenia compared to healthy controls","volume":"122","author":"Lehrer","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib95","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.pscychresns.2006.05.009","article-title":"Dopamine D2 receptor binding in drug-naive patients with schizophrenia examined with raclopride-C11 and positron emission tomography","volume":"148","author":"Talvik","year":"2006","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib96","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00406-006-0649-3","article-title":"Midbrain dopamine D2\/3 receptor binding in schizophrenia","volume":"256","author":"Tuppurainen","year":"2006","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib97","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/npp.2008.199","article-title":"The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study","volume":"34","author":"Graff-Guerrero","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib98","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.schres.2006.03.042","article-title":"D2\/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia","volume":"85","author":"Buchsbaum","year":"2006","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib99","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1176\/appi.ajp.161.6.1016","article-title":"Low dopamine D(2) receptor binding in subregions of the thalamus in schizophrenia","volume":"161","author":"Yasuno","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib100","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/01.WCB.0000048520.34839.1A","article-title":"Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: Amphetamine-induced dopamine release in the functional subdivisions of the striatum","volume":"23","author":"Martinez","year":"2003","journal-title":"J Cereb Blood Flow Metabol"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib101","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2009.129","article-title":"The reward circuit: Linking primate anatomy and human imaging","volume":"35","author":"Haber","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib102","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0306-4522(99)00575-8","article-title":"The connections of the dopaminergic system with the striatum in rats and primates: An analysis with respect to the functional and compartmental organization of the striatum","volume":"96","author":"Joel","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0924-8196(05)80005-3","article-title":"The organization and circuits of mesencephalic dopaminergic neurons and the distribution of dopamine receptors in the brain","volume":"21","author":"Bentivoglio","year":"2005","journal-title":"Handbook of Chemical Neuroanatomy"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib104","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuroscience.2011.08.066","article-title":"Dopamine release in the basal ganglia","volume":"198","author":"Rice","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib105","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.neuron.2008.01.022","article-title":"Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system","volume":"57","author":"Lammel","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib106","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/cne.903620308","article-title":"Subsets of midbrain dopaminergic neurons in monkeys are distinguished by different levels of mRNA for the dopamine transporter: Comparison with the mRNA for the D2 receptor, tyrosine hydroxylase and calbindin immunoreactivity","volume":"362","author":"Haber","year":"1995","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib107","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/syn.20506","article-title":"Small effect of dopamine release and no effect of dopamine depletion on [18F]fallypride binding in healthy humans","volume":"62","author":"Cropley","year":"2008","journal-title":"Synapse"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib108","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1038\/npp.2008.33","article-title":"Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride","volume":"33","author":"Kegeles","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib109","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.biopsych.2007.03.022","article-title":"Estimation of baseline dopamine D2 receptor occupancy in striatum and extrastriatal regions in humans with positron emission tomography with [18F] fallypride","volume":"63","author":"Riccardi","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib110","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/syn.20734","article-title":"Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride","volume":"64","author":"Slifstein","year":"2010","journal-title":"Synapse"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib111","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.neuron.2013.12.027","article-title":"Dopamine neurons control striatal cholinergic neurons via regionally heterogeneous dopamine and glutamate signaling","volume":"81","author":"Chuhma","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12762","article-title":"Cholinergic interneurons in the dorsal and ventral striatum: Anatomical and functional considerations in normal and diseased conditions","volume":"1349","author":"Gonzales","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib113","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.neuron.2015.11.010","article-title":"Enkephalin disinhibits mu opioid receptor-rich striatal patches via delta opioid receptors","volume":"88","author":"Banghart","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib114","doi-asserted-by":"crossref","first-page":"9017","DOI":"10.1523\/JNEUROSCI.0870-15.2015","article-title":"Substance P weights striatal dopamine transmission differently within the striosome-matrix axis","volume":"35","author":"Brimblecombe","year":"2015","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib115","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0166-2236(91)90179-X","article-title":"Dopaminergic innervation of the cerebral cortex: Unexpected differences between rodents and primates","volume":"14","author":"Berger","year":"1991","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib116","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.neuron.2012.09.023","article-title":"Dopaminergic modulation of synaptic transmission in cortex and striatum","volume":"76","author":"Tritsch","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib117","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0896-6273(02)00967-4","article-title":"Getting formal with dopamine and reward","volume":"36","author":"Schultz","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib118","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00429-014-0901-y","article-title":"Mapping dopaminergic deficiencies in the substantia nigra\/ventral tegmental area in schizophrenia","volume":"221","author":"Rice","year":"2016","journal-title":"Brain Struct Funct"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib119","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0006-3223(99)00282-6","article-title":"Decreased density of tyrosine hydroxylase-immunoreactive axons in the entorhinal cortex of schizophrenic subjects","volume":"47","author":"Akil","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib120","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.molbrainres.2003.11.004","article-title":"Expression of the ionotropic glutamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia","volume":"121","author":"Mueller","year":"2004","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib121","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF02250926","article-title":"Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson\u2019s disease and schizophrenia","volume":"8","author":"Ichinose","year":"1994","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib122","doi-asserted-by":"crossref","first-page":"9006","DOI":"10.1073\/pnas.86.22.9006","article-title":"Distinct presynaptic control of dopamine release in striosomal and matrix areas of the cat caudate nucleus","volume":"86","author":"Kemel","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib123","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1073\/pnas.75.11.5723","article-title":"Histochemically distinct compartments in the striatum of human, monkeys, and cat demonstrated by acetylthiocholinesterase staining","volume":"75","author":"Graybiel","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib124","first-page":"287","article-title":"Basal ganglia pathology in schizophrenia: Dopamine connections and anomalies","volume":"113","author":"Perez-Costas","year":"2010"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib125","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3389\/fnana.2011.00059","article-title":"Basal ganglia disorders associated with imbalances in the striatal striosome and matrix compartments","volume":"5","author":"Crittenden","year":"2011","journal-title":"Front Neuroanat"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib126","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3389\/fnana.2011.00059","article-title":"\u201cPrefrontal\u201d cognitive performance of healthy subjects positively correlates with cerebral FDOPA influx: An exploratory [18F]-fluoro-L-DOPA-PET investigation","volume":"28","author":"Vernaleken","year":"2007","journal-title":"Hum Brain Mapp"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib127","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1523\/JNEUROSCI.4475-07.2008","article-title":"Working memory capacity predicts dopamine synthesis capacity in the human striatum","volume":"28","author":"Cools","year":"2008","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib128","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1523\/JNEUROSCI.4467-08.2009","article-title":"Striatal dopamine predicts outcome-specific reversal learning and its sensitivity to dopaminergic drug administration","volume":"29","author":"Cools","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2016.03.2104_bib129","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1073\/pnas.1417219112","article-title":"Ventral striatal dopamine reflects behavioral and neural signatures of model-based control during sequential decision making","volume":"112","author":"Deserno","year":"2015","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322316322375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322316322375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T22:43:17Z","timestamp":1748817797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322316322375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":129,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0006322316322375"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2016.03.2104","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}